The Asia Pacific Ulcerative Colitis Market would witness market growth of 6.4% CAGR during the forecast period (2022-2028).
Fever, headache, rashes, low blood pressure, breathing difficulty, back discomfort, and stomach pain are all possible side effects of these genetically modified medications. Furthermore, these medicines may impair the body's ability to fight illness. The specific aetiology of ulcerative colitis is unknown, but hereditary causes, environmental changes, or a weaker immune system are all possibilities. Simple healthy practices like eating short meals throughout the day, staying hydrated throughout the day, avoiding greasy foods, and reducing high-fiber food intake can help to prevent ulcerative colitis.
The two key reasons driving the growth of the ulcerative colitis market are rising awareness and concerns about patients' health, as well as the advent of a significant number of pipeline compounds and government initiatives. Ulcerative colitis is a chronic condition that affects the large intestine, sometimes known as the colon. Ulcerative colitis is a disease in which the large intestine becomes inflamed, causing stomach pain, blood in the stool, and diarrhea. The market is growing because of the rising prevalence of ulcerative colitis around the world. Higher spending on research and development capacity to produce breakthrough therapies is also helping the market. The expansion of the ulcerative colitis therapy industry is also being fueled by increased efforts by governmental and non-governmental organizations to do biologics research.
The APAC region is witnessing a rising prevalence of Crohn's disease and ulcerative colitis in the region, increased prescription of biosimilars, and rising innovative medication approval. Men have a higher prevalence of Crohn's disease than women, according to a study published in NCBI. East Asia, which encompasses Japan, Korea, China, and other countries, has the highest prevalence of inflammatory bowel diseases.
The pharmaceutical industry is finding it difficult to obtain raw materials and components from the Chinese market as a result of China's economic crisis. Even while some companies in China have reopened, crucial parts and raw materials are still in limited supply. As a result, different enterprises that import minor components and other elements to build finished products are seeing their margins and profitability suffer. In the short term, this aspect could put increasing pressure on drug prices. However, the COVID-19 pandemic has eventually presented a unique opportunity to investigate business from a different perspective. There is a chance that the principal producer and supplier of APIs, IVDs, and generic pharmaceuticals will transfer from China to India.
The China market dominated the Asia Pacific Ulcerative Colitis Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $703.2 million by 2028. The Japan market is anticipated to grow at a CAGR of 5.8% during (2022 - 2028). Additionally, The India market would showcase a CAGR of 7.1% during (2022 - 2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Ulcerative Colitis Market is Projected to reach USD 9 Billion by 2028, at a CAGR of 5.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Scope of the Study
Market Segments Covered in the Report:
ByMolecule Type
- Small Molecules
- Biologics
By Disease Type
By Route of Administration
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Ulcerative Colitis Market, by Molecule Type
1.4.2 Asia Pacific Ulcerative Colitis Market, by Disease Type
1.4.3 Asia Pacific Ulcerative Colitis Market, by Route of Administration
1.4.4 Asia Pacific Ulcerative Colitis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies deployed in Ulcerative Colitis Market
Chapter 4. Asia Pacific Ulcerative Colitis Market by Molecule Type
4.1 Asia Pacific Small Molecules Market by Country
4.2 Asia Pacific Biologics Market by Country
Chapter 5. Asia Pacific Ulcerative Colitis Market by Disease Type
5.1 Asia Pacific Mild Market by Country
5.2 Asia Pacific Moderate Market by Country
5.3 Asia Pacific Severe Market by Country
Chapter 6. Asia Pacific Ulcerative Colitis Market by Route of Administration
6.1 Asia Pacific Oral Market by Country
6.2 Asia Pacific Injectables Market by Country
Chapter 7. Asia Pacific Ulcerative Colitis Market by Country
7.1 China Ulcerative Colitis Market
7.1.1 China Ulcerative Colitis Market by Molecule Type
7.1.2 China Ulcerative Colitis Market by Disease Type
7.1.3 China Ulcerative Colitis Market by Route of Administration
7.2 Japan Ulcerative Colitis Market
7.2.1 Japan Ulcerative Colitis Market by Molecule Type
7.2.2 Japan Ulcerative Colitis Market by Disease Type
7.2.3 Japan Ulcerative Colitis Market by Route of Administration
7.3 India Ulcerative Colitis Market
7.3.1 India Ulcerative Colitis Market by Molecule Type
7.3.2 India Ulcerative Colitis Market by Disease Type
7.3.3 India Ulcerative Colitis Market by Route of Administration
7.4 South Korea Ulcerative Colitis Market
7.4.1 South Korea Ulcerative Colitis Market by Molecule Type
7.4.2 South Korea Ulcerative Colitis Market by Disease Type
7.4.3 South Korea Ulcerative Colitis Market by Route of Administration
7.5 Singapore Ulcerative Colitis Market
7.5.1 Singapore Ulcerative Colitis Market by Molecule Type
7.5.2 Singapore Ulcerative Colitis Market by Disease Type
7.5.3 Singapore Ulcerative Colitis Market by Route of Administration
7.6 Malaysia Ulcerative Colitis Market
7.6.1 Malaysia Ulcerative Colitis Market by Molecule Type
7.6.2 Malaysia Ulcerative Colitis Market by Disease Type
7.6.3 Malaysia Ulcerative Colitis Market by Route of Administration
7.7 Rest of Asia Pacific Ulcerative Colitis Market
7.7.1 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type
7.7.2 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type
7.7.3 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration
Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Ajinomoto Co., Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental & Regional Analysis
8.2.4 Research & Development Expenses
8.3 AstraZeneca PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.4 GlaxoSmithKline PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.5 Johnson & Johnson
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental &Regional Analysis
8.5.4 Research & Development Expenses
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Pfizer, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Approvals and Trials:
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 InDex Pharmaceuticals Holding AB
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Recent strategies and developments:
8.9.3.1 Partnerships, Collaborations, and Agreements:
8.10. Eli Lilly And Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
TABLE 1 Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Mild Market by Country, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Mild Market by Country, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Moderate Market by Country, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Moderate Market by Country, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Severe Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Severe Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
TABLE 21 Asia Pacific Injectables Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific Injectables Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 25 China Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 26 China Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 27 China Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 28 China Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 29 China Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 30 China Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 31 China Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 32 China Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 33 Japan Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 34 Japan Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 35 Japan Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 36 Japan Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 37 Japan Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 Japan Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 Japan Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 40 Japan Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 41 India Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 42 India Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 43 India Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 44 India Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 45 India Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 India Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 India Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 India Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 South Korea Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 50 South Korea Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 51 South Korea Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 52 South Korea Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 53 South Korea Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 South Korea Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 South Korea Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 56 South Korea Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 57 Singapore Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 58 Singapore Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 59 Singapore Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 60 Singapore Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 61 Singapore Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 Singapore Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 Singapore Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 64 Singapore Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 65 Malaysia Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 66 Malaysia Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 67 Malaysia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 68 Malaysia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 69 Malaysia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 Malaysia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 Malaysia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 Malaysia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 Rest of Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 74 Rest of Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 75 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 76 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 77 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 80 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 81 Key Information – Abbott Laboratories
TABLE 82 Key information – Ajinomoto Co., Inc.
TABLE 83 KEY INFORMATION – ASTRAZENECA PLC
TABLE 84 Key Information – GlaxoSmithKline PLC
TABLE 85 Key information – Johnson & Johnson
TABLE 86 KEY INFORMATION - MERCK & CO., INC.
TABLE 87 Key Information – Pfizer, Inc.
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key Information – InDex Pharmaceuticals Holding AB
TABLE 90 Key Information – Eli Lilly And Company
List of Figures
FIG 1 Methodology for the research